JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Затворен

2.78 2.96

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.5

Максимум

2.7800000000000002

Ключови измерители
By Trading Economics
Служители	26

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+435.71% upside

Дивиденти
By Dow Jones
Следващи печалби	11.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	261K 21M
Предишно отваряне	-0.18
Предишно затваряне	2.78

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.10.2025 г., 23:50 ч. UTC

Горещи акции

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28.10.2025 г., 23:25 ч. UTC

Печалби

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28.10.2025 г., 23:18 ч. UTC

Печалби

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28.10.2025 г., 22:20 ч. UTC

Печалби

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28.10.2025 г., 22:13 ч. UTC

Печалби

Wal-Mart de Mexico Net Profit Falls in 3Q

28.10.2025 г., 21:38 ч. UTC

Печалби

Correction to Visa Sales Jump Article

28.10.2025 г., 21:17 ч. UTC

Печалби

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28.10.2025 г., 21:07 ч. UTC

Печалби

Visa Sales Jump as Consumers Keep Spending -- Update

28.10.2025 г., 21:02 ч. UTC

Печалби

Mondelez Tempers Outlook as Costs Rise

28.10.2025 г., 23:51 ч. UTC

Пазарно говорене

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28.10.2025 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28.10.2025 г., 23:02 ч. UTC

Печалби

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28.10.2025 г., 23:01 ч. UTC

Печалби

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28.10.2025 г., 22:46 ч. UTC

Печалби

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28.10.2025 г., 22:45 ч. UTC

Печалби

SK Hynix 3Q Net KRW12.6T >000660.SE

28.10.2025 г., 22:44 ч. UTC

Печалби

SK Hynix 3Q Rev KRW24.44T >000660.SE

28.10.2025 г., 22:43 ч. UTC

Печалби

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28.10.2025 г., 22:42 ч. UTC

Печалби

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28.10.2025 г., 22:40 ч. UTC

Печалби

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28.10.2025 г., 22:40 ч. UTC

Печалби

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28.10.2025 г., 22:20 ч. UTC

Печалби

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28.10.2025 г., 22:02 ч. UTC

Печалби

Review & Preview: Earnings Extravaganza -- Barrons.com

28.10.2025 г., 21:42 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

28.10.2025 г., 21:42 ч. UTC

Пазарно говорене

Печалби

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28.10.2025 г., 21:20 ч. UTC

Печалби

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28.10.2025 г., 21:19 ч. UTC

Печалби

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28.10.2025 г., 21:18 ч. UTC

Печалби

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Ценова цел

By TipRanks

435.71% нагоре

12-месечна прогноза

Среден 15 USD 435.71%

Висок 15 USD

Нисък 15 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Lisata Therapeutics през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.